Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Gains from Sales and Divestitures (2012 - 2025)

Lemaitre Vascular (LMAT) reported Gains from Sales and Divestitures of $22429.0 for Q4 2025, down 54.71% year-over-year from $49521.0 in Q4 2024, and down 54.71% on a QoQ basis from $49521.0 in Q4 2024.

Lemaitre Vascular (LMAT) has 12 years of Gains from Sales and Divestitures data on file, last reported at $22429.0 in Q4 2025.

  • Quarterly Gains from Sales and Divestitures fell 54.71% year-over-year to $22429.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22429.0 (down 54.71% YoY) and the FY2025 annual result came in at $22429.0, down 54.71% from the prior year.
  • Gains from Sales and Divestitures eased to $22429.0 in Q4 2025 per LMAT's latest filing, from $49521.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $49521.0 in Q4 2024 and bottomed at $22429.0 in Q4 2025.
  • The 3-year median for Gains from Sales and Divestitures is $45489.0 (2022), against an average of $39146.3.
  • Peak annual rise in Gains from Sales and Divestitures reached 54.71% in 2025, while the deepest fall reached 54.71% in 2025.
  • Tracing LMAT's Gains from Sales and Divestitures over 3 years: stood at $45489.0 in 2022, then gained by 8.86% to $49521.0 in 2024, then sank by 54.71% to $22429.0 in 2025.
  • Per Business Quant, the three latest LMAT Gains from Sales and Divestitures figures stand at $22429.0 (Q4 2025), $49521.0 (Q4 2024), and $45489.0 (Q4 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn
10 Lemaitre Vascular 2.28 Bn 1.91 Bn 48.40 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 22,429.00
Dec 31, 2025 22,429.00
Dec 31, 2024 49,521.00
Dec 31, 2024 49,521.00
Dec 31, 2022 45,489.00
Dec 31, 2022 45,489.00
Dec 31, 2020 50,669.00
Dec 31, 2020 50,669.00
Dec 31, 2019 61,058.00
Dec 31, 2019 61,058.00
Dec 31, 2018 63,478.00
Dec 31, 2018 63,478.00
Dec 31, 2017 68,992.00
Dec 31, 2017 68,992.00
Dec 31, 2016 58,341.00
Dec 31, 2016 58,341.00
Dec 31, 2015 61,362.00
Dec 31, 2015 61,362.00
Dec 31, 2014 71,542.00
Dec 31, 2014 71,542.00
Dec 31, 2013 112,284.00
Dec 31, 2013 112,284.00
Dec 31, 2012 123,259.00
Dec 31, 2012 123,259.00